European Society of Toxicology In Vitro > News > ESTIV and ONTOX signs Memorandum of Understanding
29 October 2021

ESTIV and ONTOX signs Memorandum of Understanding

Scope of Collaboration

ESTIV and ONTOX entered into the MoU to jointly conduct the following activities:

  • to share appropriate information related to the activities in the field of research on NAMs to adequate target audiences
  • to jointly organise events with clear mutual benefits for ESTIV and for ONTOX.

The MoU has been signed on 19 October 2021 by ESTIV President, Dr. Helena Kandarova and ONTOX Project Coordinator, Prof. Mathieu Vinken (VUB).


ONTOX is conducting a research project in the context of the European H2020 Research and Innovation Programme SC1-BHC-11-2020 called “Advancing the safety assessment of chemicals without the use of animal testing”. The vision of the ONTOX consortium is to provide a functional and sustainable solution for advancing human risk assessment of chemicals without the use of animals in line with the principles of 21st century toxicity testing and next generation risk assessment. More at: www.ontox-project.eu

Related content

ESTIV – ASCCT Webinar: NAMs and Medical Devices – Challenges and Successes

We are thrilled to have Kelly Coleman, PhD, DABT, and Lindsey Borton, MPH, DABT…

2026 ESTIV Applied Training Course – the early-bird registration deadline is approaching!

The deadline for the reduced registration fee is approaching fast — 31 July is the last day! 🚨

The ESTIV 2026 Special Issue is open for submissions

Toxicology in Vitro is now accepting manuscripts for the Special Issue arising from the ESTIV 2026 Congress held in Maastricht. The collection takes its direction from the congress theme — “Ensuring Safety, Advancing Science: Bridging to the Future with NAMs” — and is open until 31 December 2026.

Silver Sponsor

Communication partners

Memorandum of Understanding